No profile data available.
Intellia Therapeutics, Inc. (NTLA) is a healthcare company in the multi-therapeutic drug manufacturing industry, based in Cambridge, United States, with about 377 full-time employees.
It reported revenue of $67.67 million for fiscal year 2025, up 16.9% from fiscal year 2024, and net income of -$412.69 million. Its market capitalization was $1.83 billion as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing.
Intellia Therapeutics reported $67.67 million in revenue for fiscal year 2025, up 16.9% from $57.88 million in fiscal year 2024.
$1.83 billion as of October 9, 2026.
Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Prestige Consumer Healthcare Inc. (PBH), Bausch Health Companies Inc. (BHC), Perrigo Company plc (PRGO), Xencor, Inc. (XNCR).